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Abstract
Several transgenic mice models solidly support the hypothesis that HER2 (ERBB2) overexpression or mutation promotes
tumorigenesis. Recently, a HER2 splice variant lacking exon-16 (D16HER2) has been detected in human breast carcinomas.
This alternative protein, a normal byproduct of HER2, has an increased transforming potency compared to wild-type (wt)
HER2 receptors. To examine the ability of D16HER2 to transform mammary epithelium in vivo and to monitor D16HER2-
driven tumorigenesis in live mice, we generated and characterized a mouse line that transgenically expresses both human
D16HER2 and firefly luciferase under the transcriptional control of the MMTV promoter. All the transgenic females
developed multifocal mammary tumors with a rapid onset and an average latency of 15.11 weeks. Immunohistochemical
analysis revealed the concurrent expression of luciferase and the human D16HER2 oncogene only in the mammary gland
and in strict correlation with tumor development. Transgenic D16HER2 expressed on the tumor cell plasma membrane from
spontaneous mammary adenocarcinomas formed constitutively active homodimers able to activate the oncogenic signal
transduction pathway mediated through Src kinase. These new transgenic animals demonstrate the ability of the human
D16HER2 isoform to transform ‘‘per se’’ mammary epithelium in vivo. The high tumor incidence as well as the short latency
strongly suggests that the D16HER2 splice variant represents the transforming form of the HER2 oncoprotein.
Citation: Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, et al. (2011) The Human Splice Variant D16HER2 Induces Rapid Tumor Onset in a Reporter
Transgenic Mouse. PLoS ONE 6(4): e18727. doi:10.1371/journal.pone.0018727
Editor: Maria G. Castro, University of California, Los Angeles, and Cedars-Sinai Medical Center, United States of America
Received October 11, 2010; Accepted March 16, 2011; Published April 29, 2011
Copyright:  2011 Marchini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Ministero dell’Universita ` e della Ricerca, FIRB 2003 (RBLA03KWBS_005). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: augusto.amici@unicam.it
. These authors contributed equally to this work.
Introduction
Numerous studies estimate that the oncogene HER2 is
overexpressed in 20–30% of primary breast cancers and this
alteration correlates with poor prognosis [1]. Further support for
the involvement of HER2 in the initiation and progression of
breast cancer comes from analysis of transgenic mice generated by
targeting overexpression of activated neu (the rat homolog of
HER2) to the mammary gland under the control of the murine
mammary tumor virus (MMTV) promoter [2]. Activated neu is a
mutated form with valine instead of glutamic acid at residue 664 in
the transmembrane domain. Although rapid onset (11–13 weeks)
of multifocal mammary tumors was observed in the majority of
activated neu transgenic mice, this mutation has never been
observed in human cancers, which only present amplification of
the HER2 gene copy number and consequent overexpression of
HER2 protein on the cell membrane. In wt neu-expressing mice
under the MMTV promoter, focal mammary tumors arise next to
hyperplastic mammary tissue after a long latency period (17–48
weeks) [3], suggesting that genetic alterations in addition to that
inducing HER2 overexpression are required for mammary
transformation. Notably, tumors in these transgenic mice arose
only when the oncoprotein carried mutations involving small
deletions in the extracellular domain that promote HER2/neu
transforming activity through formation of intermolecular disulfide
bonds [4]. More recently, transgenic mice were generated with wt
human HER2 under the whey acidic protein promoter; however
while HER2 was expressed in the mammary glands, no mammary
neoplastic transformation was ever detected in any animal [5].
Another human wt HER2 transgenic model under the direction of
MMTV developed human HER2-overexpressing breast tumors
but with a long latency of about 28.6 weeks [6]. Sequencing of the
human HER2 transcripts from primary mammary tumors that
developed in the transgenic founder mouse revealed an in-frame
15-bp deletion in the wt HER2 juxtamembrane region potentially
affecting cysteine-mediated dimerization. In this context, recent
studies have reported that overexpression of HER2 alone does not
seem sufficient to generate mammary tumors in mice and requires
activating mutations that affect the number of cysteines to become
oncogenic [7]. Indeed, it has been reported that expression of wt
611-carboxy-terminal fragments (CTF) in the mouse mammary
gland led to the development of aggressive tumors [7], suggesting a
causal role for CTF in tumorigenesis based on their ability to
constitutively homodimerize.
Interestingly, an alternative splice form of human HER2 gene,
D16HER2, containing an in-frame deletion in the same region
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been detected in human breast carcinomas [8,9]. This deletion
removes the relevant cysteine residues in HER2, disrupting the
disulfide bond structure of the protein and leaving the remaining
unpaired cysteine residues available for intermolecular bonding.
For this reason, D16HER2 represents a constitutively active form
similar to the mutated neu gene [8]. D16HER2 transcripts have
been detected in a majority of breast tumors and reported to
comprise 4–9% of total HER2 transcripts [9,10,11]. Moreover,
this oncogenic isoform has been associated with trastuzumab
resistance [10]. Transformation associated with HER2 overex-
pression might reflect the increase in absolute levels of this splice
variant to a critical threshold for constitutive activation of HER2.
Here, we describe the generation and characterization of a new
reporter transgenic mouse that expresses both the human
D16HER2 splice isoform and the firefly luciferase under the
transcriptional control of the MMTV promoter. Analyses of these
genetically engineered mice demonstrate that D16HER2 consti-
tutively homodimerizes on the tumor cell plasma membrane and is
able to transform mammary epithelium in vivo through the
oncogenic properties mediated by the downstream Src kinase
signaling circuitry, making this splice variant a likely candidate for
the transforming form of the HER2 oncoprotein.
Results and Discussion
Generation and characterization of the human D16HER2-
LUC transgenic mice
We generated a D16HER2-LUC transgenic mouse using a
bicistronic vector containing an IRES sequence between the
human D16HER2 and the firefly luciferase genes to ensure their
coordinated expression driven by the same MMTV promoter
(Fig. 1A). Luciferase was chosen as a reporter since it is rapidly
identified by optical imaging in live organisms and simultaneously
allows accurate quantitation in tissue extracts and immunohisto-
chemical detection with specific antibodies. Expression of
luciferase and D16HER2 was verified on NIH3T3, HEK293
and MDAMB435 transfected cells before transgenic mouse
generation (Fig. S1). The transgene was determined to have
integrated at a single site, precisely at 85.72 Mb, on murine
chromosome 5, region E-1 (NT109320.4), inside an intergenic
region, NCBI Build m37.1 (Fig. 1B). BLAST analysis of this
intergenic region revealed that it contains neither genes nor
regulatory sequences. Transgene random insertion was found to
have occurred exactly 1.17 Mb downstream of the non-histone
chromosomal protein HMG-17-like gene and 718 Kb upstream of
the centromere protein C1 gene. The great distance between the
transgene and these predicted genes ensures that the insertion itself
does not affect the tumorigenesis. Quantitative PCR analysis
revealed a transgene copy number of 5. The founder female
developed 8 spontaneous mammary tumors, starting at 18 weeks
of age, and as expected, tumor localization was visualized in the
live animal by bioluminescence analysis (Fig. 1E).
Because the MMTV promoter is hormonally regulated and
tumor development in founder female might be enhanced by
increased transgene expression in the mammary gland during
pregnancy and lactation, we monitored the development of
spontaneous mammary tumors by palpation in virgin females,
starting from F2 generation of the transgenic line (see Materials
and Methods). All transgenic females (n=20) developed multiple
asynchronous mammary tumors (4–5 tumors/mouse) between 12
and 19 weeks of age (Fig. S2A), with similar results in the F3
generation (n=13). Transgenic virgin females, currently at the F4
generation, maintain that tumor onset schedule, with an average
latency of 15.1162.5 weeks (mean 6 SD) (n=35), indicating that
the formation of D16HER2-overexpressing mammary tumors is a
reproducible phenotype in D16HER2-LUC transgenic mice.
Mammary tumors grew continuously, reaching 1–1.5 cm
3 in a
matter of weeks, as shown by mammary tumor growth curves (Fig.
S2B). Sequencing of the transgenic HER2 transcript from
mammary tumors confirmed the in-frame 48-bp deletion in the
HER2 juxtamembranous region, eliminating amino acids 634 to
649. Of note, only a few transgene copies (only 5 copies were
detected) are sufficient to drive neoplastic transformation of
mammary epithelial cells in D16HER2-LUC mice, whereas 30–50
wtHER2 transgene copies are reportedly necessary to induce
breast cancer in about 80% of MMTV-wtHER2 transgenic mice
[6]. Since the D16HER2 splice variant represents about 10% of
total HER2 transcript in human breast carcinoma, it is plausible
that malignant transformation ensues when a critical threshold of
D16HER2 is reached in mammary cells presenting HER2 gene
amplification. Histologically, these fast-growing tumors were
classified as invasive HER2-positive adenocarcinomas. Immuno-
histochemical analysis confirmed the concurrent expression of the
human D16HER2 oncogene (Fig. 1F) and the luciferase gene
(Fig. 1G) and revealed the specific staining for epithelial cells but
not for stromal cells or adipocytes, although non-neoplastic
mammary ducts were negative (Fig. 1F and G). Tumors consisted
of cells with round nuclei and eosinophilic cytoplasm growing in
solid sheets and packets traversed by delicate fibrovascular septa.
Growth of these unencapsulated tumors compressed the sur-
rounding tissues (Fig. 1F and G). Tumor-bearing transgenic
females developed lung metastases beginning at 25 weeks of age
(Fig. S3), suggesting particularly aggressive tumor behavior upon
expression of the D16HER2 splice variant. The histological
features of these pulmonary metastatic lesions were consistent
with a primary breast tumor origin, with robust staining for HER2
and luciferase demonstrating high-level transgene expression (Fig.
S3 middle and right panels, respectively). Although the MMTV
promoter is noted for its targeted expression in mammary glands,
its expression pattern in other tissues has been reported [6,9,12].
The tissue specificity of the transgene expression was verified by
immunohistochemical analysis of the HER2 and luciferase
expression pattern in mammary glands of D16HER2-LUC
transgenic females (F2 generation) and also in other tissues,
including brain, salivary glands, lymphoid compartment, repro-
ductive organs, kidney, heart, lung, liver, stomach, intestine
(Table 1). HER2 expression was detected only in the mammary
gland and showed a strict correlation with tumor development.
Although ovaries and uterus tissue sections showed a positive
staining for HER2, they were negative for luciferase, suggesting
that the transgene is not espressed in these tissues; the HER2
positivity might reflect cross-reactivity of anti-HER2 antibody with
the murine HER2/neu protein. All tissues appeared architectur-
ally normal, with invasive adenocarcinomas observed only in the
mammary gland.
D16HER2 forms disulfide-bridged homodimers in
D16HER2-LUC mammary tumors
Western blot analysis of lysates of cells isolated ex vivo from 4
tumors obtained from 4 different mice revealed the presence of
D16HER2 dimers migrating above 225 kDa (HER2 D) and the
phosphorylation of D16HER2 D (p-HER2 D) in all samples under
non-reducing conditions (Fig. 2A, lanes 1–4). The analysis of the
plasma membrane component purified from the same D16HER2-
positive tumor samples pooled to obtain an adequate amount of
protein extracts revealed formation of stable, constitutively active
D16HER2 homodimers on the tumor cell surface (Fig. 2C).
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counterpart both on whole lysates and plasma membrane extracts
(Fig. 2C subpanel a, lanes 1 and 2, respectively), while both HER2
M and HER2 D were significantly more activated in the plasma
membrane fraction than in crude tumor lysate (Fig. 2C subpanel
b, lanes 2 and 1, respectively). E-cadherin was used as a plasma
membrane marker. Analysis to determine whether D16HER2
expression leads to activation of oncogenic signal transduction
pathways known to function downstream of constitutively
activated HER2, such as mitogen-activated protein kinase
(MAPK), AKT, Src kinase and STAT3, showed that, consistent
with data reported in in vitro models [10], the oncogenic properties
of D16HER2 were mediated through Src kinase (Fig. 2B, lanes 1–
4). In our in vivo model, Src kinase activation was combined with
that of STAT3, a downstream signal transducer in Src family
kinase-mediated tumorigenesis [13]. Comparison of the signaling
activity of D16HER2 with that of wtHER2 using BT474 (HER2-
positive) and ZR75.1 (nearly HER2-negative) tumor extracts
(Fig. 2A and B, lanes 5 and 6, respectively) revealed mainly
activated MAPK- and AKT-mediated signaling circuitries. These
findings suggest a mechanism through which the disulfide-bond
homodimerized D16HER2 amplifies HER2 transforming poten-
tial, providing a crucial cell growth advantage.
Bioluminescence analysis is predictive of tumor onset in
human D16HER2-LUC transgenic mice
D16HER2-LUC transgenic females were monitored for lucif-
erase activity starting from 8 weeks of age. Bioluminescence
analysis revealed luciferase activity in mammary glands of these
mice one month before tumors became palpable (Fig. 3A),
suggesting that luciferase reporter expression detected by such
analysis might be predictive of tumor onset. Whole-mount (Fig. 3B)
and histological (Fig. 3C–E) analysis of mammary glands
confirmed the presence of small neoplastic masses, and immuno-
histochemical analysis of these non-palpable tumors revealed the
expression of the HER2 protein (Fig. 3D). Whole-mount analysis
of the mammary glands revealed 2 to 5 variously sized tumor
masses arising preferentially from the ducts closest to the nipple.
Figure 1. D16HER2-LUC transgenic mice develop spontaneous mammary tumors. (A) Schematic representation of the MMTV-driven
human D16HER2-LUC transgene, with the MMTV LTR promoter (pMMTV, red), the human D16HER2 cDNA (green), the IRES (internal ribosome entry
site, yellow), the luciferase cDNA (LUC, purple), and the termination signal from the SV40 (Poly A, blue). Relevant restriction sites are indicated. (B)
Graphic representation of murine chromosome 5 divided into A–G regions and numbered subregions, showing that the transgene integrates in
region E-1. (C, D) An F2 female transgenic mouse with primary breast tumors (arrows) just before tumor removal. (E) Bioluminescence analysis of a 28-
week-old tumor-bearing D16HER2-LUC transgenic mouse (founder female), using the in VivoVision Systems, Xenogen. (F and G)
Immunohistochemical detection of HER2 and luciferase, respectively, showing strong and uniform expression of both proteins in sections of a
mammary tumor, while the normal duct on the right appears negative. Magnification: 6400.
doi:10.1371/journal.pone.0018727.g001
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for the human transgene, staining in the small tumors was
homogeneously distributed in the tumor parenchyma. Finally,
HER2 expression correlated with that of PCNA, which detects
mitotic activity of transformed epithelial cells (Fig. 3E), suggesting
that HER2 expression and hyperplasia are concomitant.
In conclusion, the high tumor incidence, the rapid tumor
growth, as well as the significantly shorter latency period (15.11 vs
28.6 weeks) in our D16HER2 transgenic mice as compared with
MMTV-wtHER2 transgenic mice described by Finkle et al. [6],
strongly supports the candidacy of the D16HER2 splice variant as
the transforming form of the HER2 oncoprotein. Indeed, the
strong immunohistochemical staining for the transgene in tumor
tissue, but not in non-neoplastic mammary ducts or in other
tissues, supports the notion that expression of D16HER2 in the
mammary gland is sufficient to induce malignant transformation
in a single step. Conversely, support for the insufficiency of
wtHER2 expression alone and without additional mutations for
full malignant transformation comes from the study by Finkle et al.
[6] who found that their transgenic mice developed mammary
tumors in a stochastic manner and that wtHER2 expression was
not confined to the tumor tissue but was also detected in
morphologically normal mammary gland and in several other
tissues. Indeed, those authors found sequence anomalies in the
juxtamembrane region of wtHER2 in .80% of mammary
tumors. The majority of these mutations affected the conserved
cysteine residues and could function as a second hit in the
transformation process in the female mammary gland [6].
The key role of the cysteine residues in the HER2 juxtamem-
brane region has been also demonstrated by Pedersen et al. [7],
who showed that transgenic expression of a HER2 carboxy-
terminal fragment (611-CTF) containing a transmembrane
domain and a short extracellular region including the sequence
deleted in D16HER2 led to the development of aggressive
mammary tumors. The mechanism of activation of 611-CTF
involved the formation of constitutive homodimers by intermo-
lecular disulfide bonding [7], consistent with our present findings.
Studies to further evaluate the role of D16HER2 in tumor
progression as well as its responsiveness to chemotherapy or
targeted therapies for HER2-overexpressing breast carcinomas
will benefit from the ability to noninvasively quantify tumor
Table 1. Tissue-specific expression of the D16HER2-LUC
transgene.
Organs HER2 Luciferase
Liver 2 2
Kidney 2 2
Adrenal gland 2 2
Spleen 2 2
Lymph-nodes 2 2
Thymus 2 2
Stomach 2 2
Thyroid 2 2
Brain 2 2
Cerebellum 2 2
Salivary glands 2 2
Uterus + 2
Trachea 2 2
Aorta 2 2
Heart 2 2
Lung 2 2
Eye 2 2
Ileum 2 2
Colon 2 2
Ovaries + 2
doi:10.1371/journal.pone.0018727.t001
Figure 2. Western blot analysis of monomeric and dimeric
D16HER2 forms and downstream signaling pathways. (A)
Protein extracts from 4 different D16HER2 tumor samples (lanes 1–4)
and breast cancer cell lines BT474 (lane 5) and ZR-75.1 (lane 6) were
separated by 4–12% gradient SDS-PAGE under non-reducing conditions
and probed, respectively, with MAb Ab3 (HER2 M and D) and PoAb anti-
phospho-HER2 p-neu (p-HER2 M and D). (B) The same protein extracts
(lanes 1–6) were analyzed under reducing conditions for activation of
the following HER2 downstream oncogenic signaling pathways: MAPK,
AKT, Src and STAT3. Actin was used to normalize protein loading. (C)
Proteins from the pool of whole D16HER2 tumor extracts (lanes 1,
subpanels a and b) and purified plasma membrane extracts (lanes 2,
subpanels a and b) were separated by 4–12% gradient SDS-PAGE under
non-reducing conditions and probed with MAb Ab3 (a) and PoAb
antiphospho-HER2 p-neu (b). E-cadherin was used as a plasma
membrane marker.
doi:10.1371/journal.pone.0018727.g002
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luciferase in our transgenic mouse model.
Materials and Methods
Generation and identification of transgenic mice
A novel bicistronic vector for in vivo examination of D16HER2
activity was designed. Each element of the expression cassette was
sequentially cloned in the pGL3 control vector (Promega, USA)
which contains the luciferase reporter gene under the control of
SV40 promoter. This vector was modified and assembled with the
following components: the MMTV promoter [2] cloned using
XhoI e NheI restriction enzymes; IRES cloned using NcoI and
XbaI restriction enzymes after elimination of the XbaI site
downstream and insertion of a new XbaI site upstream of the
luciferase gene; and D16HER2 cDNA cloned between MMTV
promoter and IRES using XhoI and XbaI restriction enzymes and
eliminating SV40 promoter. The plasmid obtained, pGL3-
MMTV-D16HER2-IRES-LUC, was sequenced to verify the
correct fragments insertion. To generate the reporter mouse for
human D16HER2, the MMTV-D16HER2-IRES-LUC expres-
sion cassette (8381 bp) was isolated from the plasmid backbone by
NheI and SalI digestions, purified and microinjected into fertilized
eggs from FVB females (Facility of the Istituto San Raffaele,
Milan, Italy). The FVB inbred mouse strain was used because of its
known suitability for transgenic experimentation and genetic
analysis [14]. Embryos were implanted into pseudopregnant CD1
surrogate mothers as described previously [15]. Founder mice (20
days of age) were shown to be transgenic by PCR using tail tissue
lysates and primer sets specific for: MMTV promoter (forward 59-
CTAAATTCAGAAGTTAGAAATGGG-39; reverse 59-CCAAA-
ACTTACTTAAGCCCTGG-39), human HER2 (forward 59-
GTGCACCGGCACAGACATGA-39; reverse 59-TTGTTCA-
GCGGGTCTCCATT-39) and luciferase (forward 59-GGAA-
GACGCAAAAACATAAAGAAA-39; reverse 59-TGAGATGT-
GACGAACGTGTACAT-39). From 37 live births, 3 positive
female mice were identified (#6157, #6177 and #6180). In these
three transgenic founders, the splice region of D16HER2
transgene was sequenced. Founder female #6157 developed 8
mammary tumors starting from 18 weeks of age, #6177 developed
only 1 mammary tumor at 20 weeks of age, and #6180 died at 20
weeks of age due to the early development of multiple mammary
tumors. Although founder #6180 was mated successfully and
carried pups to term, all pups died within one day, most likely
because this transgenic mother was unable to nurse them. The
differences in tumor multiplicity and latency among transgenic
lines generated with the same transgene construct might rest in the
random integration of the transgene into the mouse genome,
leading to different phenotypes and levels of transgene expression
depending on the site of integration and on the number of
transgene copies. The progeny from transgenic founder female
#6157 was used for this study. In a breeding program to establish
the #6157 transgenic line, an FVB non-transgenic male was
mated with the transgenic founder female and the born pups were
considered the F1 generation (founder6FVB). Sequencing of the
D16HER2 transgene splice region was done in F1 mice. To
expand the #6157 transgenic line, the transgenic male offspring of
the F1 generation were mated with non-transgenic FVB females to
obtain the F2 generation. Transgene distribution in subsequent
offspring follows Mendelian rules. Routine screening of
D16HER2-LUC transgenic mice was done using genomic DNA
extracted from tail biopsies and genotyped by PCR analysis
(primers: forward 59-GGTCTGGACGTCCCAGTGTGA-39; re-
verse 59-GATAGAATGGCGCCGGCCCTT-39). Transgenic fe-
males were monitored for mammary tumors by palpation and
tumor measurements twice weekly. Progressively growing masses
.1 mm mean diameters were considered as tumors and tumor
volume was calculated as 0.56d1
26d2, where d1 and d2 are the
smaller and larger diameters, respectively.
Mice were treated according to the European Community
guidelines. The Animal Research Committee of the University of
Camerino authorized the experimental protocol.
Figure 3. Detection of non-palpable tumors in D16HER2-LUC transgenic mice. (A) Bioluminescence analysis of an F2 female transgenic
mouse at 14 weeks of age and (B) whole-mount analysis of the inguinal mammary glands; arrows indicate non-palpable tumors. (C) Hematoxylin-
eosin and immunohistochemical staining for HER2 (D) and PCNA (E) of non-palpable mammary tumors at 14 weeks. Magnification: B,66; C–E,6400.
doi:10.1371/journal.pone.0018727.g003
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number
Transgene integration loci were examined using a restriction
enzyme-PCR-based technique [16,17] as described in Materials
and Methods S1. Transgene copy number was determined using a
method based on quantitative PCR [18].
Cell Culture
Human breast carcinoma BT474 and ZR75.1 cells, which show
HER2 oncoprotein overexpression (score 3+) and moderate
expression (score 2+), respectively, and MDAMB435 cells, which
score 0 for HER2 expression, were purchased from ATCC
(Rockville, MD). Cells were maintained in RPMI 1640 medium
(Sigma Chemical Co., St. Louis, MO) supplemented with L-
glutamine and 10% fetal calf serum (FCS) (Sigma). Murine
embryonic NIH3T3 fibroblasts was cultured in a 10% CO2
atmosphere, whereas human embryonic kidney HEK293 cells
were cultured in a 5% CO2 atmosphere in RPMI 1640 medium
(Sigma) supplemented with L-glutamine. Both lines were used
together with MDAMB435 as recipient cells for transient
transfection studies with pGL3-MMTV-D16HER2-LUC and
control pGL3 vectors. Cells were routinely tested for mycoplasma
contamination with a Mycoplasma Detection Kit (MycoAlertH,
Lonza, Rockland, ME).
Western blot analysis
Primary cultures from spontaneous tumors were lysed for 1 h
on ice in lysis buffer (50 mM Tris-HCl pH 7.2, 150 mM NaCl,
100 mM NaF, 100 mM sodium pyruvate, 1% Triton X-100)
containing protease inhibitors, 2 mM phenylmethylsulfonylfluor-
ide, 10 mg/ml aprotinin, and 2 mM Na3VO4. Protein extracts
were separated by electrophoresis on pre-cast polyacrylamide gels
(Invitrogen, Carlsbad, CA) and transferred to hydrophobic
polyvinylidene difluoride (PVDF) membranes (Amersham, Pitts-
burgh, PA). Membranes were probed with mouse monoclonal
antibodies (MAbs) Ab3 (1 mg/ml; Calbiochem, Darmstadt,
Germany), anti-Src (1:1000; Cell Signaling Technology, Beverly,
MA), anti-phospho-Stat3 (1:1000; Santa Cruz Biotechnology,
Santa Cruz, CA), anti-actin AC-40 (0.4 mg/ml; Sigma), PoAb
anti-phospho-HER2 p-Neu (tyr 1248; 0.5 mg/ml, Santa Cruz
Biotechnology), anti-phospho-p44/42 MAPK (Erk1/2; 1:2000;
Cell Signaling Technology), anti-p44/42 MAPK (Erk1/2;
1:1.000; Cell Signaling Technology), anti-phospho-Akt (Ser 473;
1:1000; Cell Signaling Technology), anti-Akt (1:1000; Cell
Signaling Technology), anti-phospho-Src (Tyr 416; 1:1000; Cell
Signaling Technology), anti-Stat3 (1:1000; Santa Cruz Biotech-
nology) and anti-E-cadherin (#4065, 1:1000; Cell Signaling
Technology).
Filters were reacted for 1 h at room temperature with HRP-
conjugated goat anti-mouse Ig (1:5000) or donkey anti-rabbit Ig
(1:10000) (Amersham GE Healthcare). Signals were detected
using enhanced chemiluminescence (ECL, Amersham GE
Healthcare).
Preparation of plasma membrane extracts
The plasma membrane fraction was separated from a pool of
three different cryopreserved spontaneous D16HER2-positive
tumors lysates using the Plasma Membrane Protein Extraction
Kit (Biovision, Mountain View, CA) according to the manufac-
turer’s instructions. The plasma membrane marker E-cadherin
was used in Western blot analysis to identify the plasma membrane
proportion of tumor cells [19,20].
Morphologic and immunohistochemical analysis
Histological evaluation was done on tissue samples fixed in 10%
neutral buffered formalin, embedded in paraffin, sectioned at
4 mm, and stained with hematoxylin-eosin solutions (Polysciences,
Inc. Warrington, PA). For immunohistochemistry, antigen retriev-
al was performed in 10 mM citric acid pH 6, for 6 min at 125uC
in Decloaking Chamber (Biocare Medical, Concord, CA) (c-erbB2
and PCNA) or for 20 min by continuous boiling in a microwave
(luciferase). Slides were incubated for 30 min with the following
primary antibodies: rabbit polyclonal anti-human c-erbB-2
oncoprotein (Dako Corp., Carpinteria, CA), mouse monoclonal
anti-PCNA oncoprotein (Dako Corp.), and rabbit polyclonal anti-
luciferase (Medical & Biological Laboratories Co., Naka-ku
Nagoya, Japan). After incubation with the appropriate biotinylated
secondary antibody, immunoreactive antigens were detected using
streptavidin-peroxidase (Thermo Scientific-Lab Vision Corpora-
tion, Fremont, CA) or MACH 3 mouse HRP-polymer RtU
(Biocare Medical) and DAB (Dako Corp.) or Bajoran Purple
(Biocare Medical) chromogen.
Whole-mount preparation
Whole-mount sections of all mammary glands were prepared as
described [21]. Briefly, mouse skin was removed and fixed
overnight in 10% buffered formalin. Mammary fat pads were
scored into quarters, gently scraped from the skin and immersed in
acetone overnight. After rehydration, samples were stained with
ferric hematoxylin (Sigma-Aldrich), dehydrated in increasing
concentrations of alcohol, cleared with histo-lemon, and stored
in methyl-salicylate (Sigma-Aldrich). Digital pictures were taken
with a Nikon Coolpix 995 (Nital) mounted on a stereoscopic
microscope (MZ6; Leica Microsystems).
Imaging protocol
Bioluminescence was measured noninvasively using the in
VivoVision Systems, IVIS 200 Series, Imaging System for small
laboratory animals (Xenogen Corp. Alameda, CA). Images were
obtained 20 min after i.p. injection of luciferin as a 10-s
acquisition. During image acquisition, mice were sedated
continuously via inhalation of 3% isoflurane. Image analysis and
bioluminescent quantification were performed using Living Image
software (Xenogen Corp.).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 5.00 for MacOSX, GraphPad Software, San Diego
California USA, www.graphpad.com.
Supporting Information
Figure S1 In vitro validation of the bicistronic expres-
sion vector pGL3-MMTV-D16HER2-LUC: luciferase as-
say and HER2 immunodetection on transfected cells. (A)
Transient transfection studies with pGL3-MMTV-D16HER2-
LUC in NIH3T3 and HEK293 cells, which have a high
transfection rate, and in MDAMB435 cells, which present a low
transfection rate, demonstrated efficient expression of luciferase,
despite attenuated expression of the gene downstream from the
IRES as compared with expression of the same gene placed in
pGL3 control vector. Data are mean 6 SEM (n=4). (B)
Expression of the MMTV-D16HER2-LUC cassette was verified
in transfected NIH3T3 fibroblasts stained with FITC-conjugated
anti-HER2 monoclonal antibody Ab3 (Oncogene), which revealed
D16HER2 protein on the cell surface.
(TIF)
A New Transgenic Mouse Model for Breast Cancer
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18727Figure S2 (A) Kaplan-Meier disease-free survival plot for F2
generation D16HER2-LUC transgenic mice. Note the incidence
of mammary tumors and the times of tumor onset (n=20). (B)
Tumor growth curve. Data are mean 6 SEM (n=5).
(TIF)
Figure S3 Pulmonary metastases. Hematoxylin-eosin (left
panel) and immunohistochemical staining for HER2 (middle
panel) and luciferase (right panel) of intravascular lung metastases
in D16HER2 transgenic mice. Tumor cell aggregates are strongly
positive for both human HER2 and luciferase staining. Magnifi-
cation: 6400.
(TIF)
Materials and Methods S1 In vitro validation of MMTV-
D16HER2-LUC expression and Determination of trans-
gene insertion site.
(DOC)
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